NBIX - Neurocrine Biosciences Inc - SEC Form 4 Insider Trading Screener

Manufactured Goods - Chemicals - Biological Products, (No Diagnostic Substances) - NBIX (914475)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
91 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
S47+1-1+1-3

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2018-03-05
NBIXLippoldt DarinGCS - Sale+OE$88.47-1,97916,062-11%-$175,090
D
2018-03-05
NBIXGano KyleChief Business Development OffS - Sale+OE$90.00-23,65078,742-23%-$2,128,500
D
2018-03-05
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$90.00-75,873135,997-36%-$6,828,570
2018-02-15
NBIXLyons Gary ADirS - Sale$84.67-5,000262,066-2%-$423,341
DM
2018-02-09
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$78.32-86,36882,942-51%-$6,764,173
D
2018-02-05
NBIXObrien Christopher FlintFormer Chief Medical OfficerS - Sale+OE$83.18-2,61355,946-4%-$217,341
2018-02-05
NBIXLyons Gary ADirS - Sale$83.08-5,000267,066-2%-$415,380
D
2018-02-05
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$83.19-96015,318-6%-$79,863
D
2018-02-05
NBIXLippoldt DarinGCS - Sale+OE$83.12-2,73716,062-15%-$227,494
D
2018-02-05
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$83.09-2,04682,942-2%-$169,997
DM
2018-02-05
NBIXGorman Kevin CharlesCEOS - Sale+OE$80.25-105,983347,033-23%-$8,504,784
D
2018-02-05
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$83.10-2,262135,997-2%-$187,977
D
2018-02-05
NBIXBenevich EricChief Commercial OfficerS - Sale+OE$83.14-8204,310-16%-$68,174
D
2018-02-05
NBIXGano KyleChief Business Development OffS - Sale+OE$83.05-2,04679,446-3%-$169,914
D
2018-01-24
NBIXRastetter William HDirS - Sale+OE$90.00-9,50024,750-28%-$855,000
2018-01-16
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$79.14-1,75050,723-3%-$138,499
2018-01-16
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$79.12-1,62579,316-2%-$128,563
2018-01-16
NBIXGorman Kevin CharlesCEOS - Sale$78.89-3,750336,357-1%-$295,820
2018-01-16
NBIXGano KyleChief Business Development OffS - Sale$79.05-1,62574,871-2%-$128,460
2018-01-16
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$79.12-1,625131,226-1%-$128,575
D
2018-01-03
NBIXLippoldt DarinGCS - Sale+OE$79.36-1,97913,157-13%-$157,053
D
2018-01-02
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$77.52-18,08413,017-58%-$1,401,823
D
2017-12-28
NBIXLippoldt DarinGCS - Sale+OE$75.00-15,23713,157-54%-$1,142,775
D
2017-12-08
NBIXLippoldt DarinGCS - Sale+OE$75.00-2,95513,157-18%-$221,625
D
2017-12-04
NBIXLippoldt DarinGCS - Sale+OE$75.04-6,27913,157-32%-$471,160
2017-12-01
NBIXLyons Gary ADirS - Sale$72.92-10,000272,066-4%-$729,182
D
2017-11-15
NBIXLippoldt DarinGCS - Sale+OE$73.05-9,90013,157-43%-$723,191
2017-11-08
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$74.58-30,00077,691-28%-$2,237,343
D
2017-11-02
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$69.71-52,81748,973-52%-$3,681,641
D
2017-11-02
NBIXGano KyleChief Business Development OffS - Sale+OE$71.05-24,81873,246-25%-$1,763,319
D
2017-10-02
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$61.04-6,92548,973-12%-$422,702
D
2017-09-06
NBIXGano KyleChief Business Development OffS - Sale+OE$60.00-20,39373,246-22%-$1,223,580
D
2017-09-06
NBIXLippoldt DarinGCS - Sale+OE$60.00-10013,157-1%-$6,000
D
2017-09-06
NBIXGano KyleChief Business Development OffS - Sale+OE$60.00-4,60773,246-6%-$276,420
D
2017-09-06
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$60.00-26,250129,601-17%-$1,575,000
D
2017-09-05
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$57.50-52,81748,973-52%-$3,036,978
D
2017-08-09
NBIXLippoldt DarinGCS - Sale+OE$55.00-5,00013,157-28%-$275,000
D
2017-08-09
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$55.00-15,354107,691-12%-$844,470
D
2017-08-04
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$50.00-22,500129,601-15%-$1,125,000
D
2017-07-27
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$50.00-8,73448,973-15%-$436,700
2017-05-23
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$53.39-10,000107,691-8%-$533,900
D
2017-05-18
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$53.32-105,63448,973-68%-$5,632,405
DM
2017-05-18
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$53.63-9,96013,017-43%-$534,155
D
2017-05-18
NBIXLippoldt DarinGCS - Sale+OE$53.27-10,00013,157-43%-$532,700
2017-05-05
NBIXNevinny Corinne HDirS - Sale$53.98-5,00034,603-13%-$269,900+2+4
2017-05-02
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$55.00-10,000117,691-8%-$550,0000-2
D
2017-05-02
NBIXGorman Kevin CharlesCEOS - Sale+OE$53.23-21,739332,607-6%-$1,157,1670-2
D
2017-05-01
NBIXGano KyleChief Business Development OffS - Sale+OE$54.00-15,00073,246-17%-$810,0000-2
2017-04-12
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$50.42-13,06548,973-21%-$658,774+2-40
2017-04-12
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale$50.42-13,06513,017-50%-$658,774+2-40
2017-04-12
NBIXLippoldt DarinGCS - Sale$50.42-13,06513,157-50%-$658,774+2-40
2017-04-12
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$50.42-13,065127,691-9%-$658,774+2-40
2017-04-12
NBIXGorman Kevin CharlesCEOS - Sale$50.42-19,596332,607-6%-$988,085+2-40
2017-04-12
NBIXGano KyleChief Business Development OffS - Sale$50.42-13,06573,246-15%-$658,774+2-40
2017-04-12
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$50.42-13,065129,601-9%-$658,774+2-40
D
2017-02-06
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale+OE$43.13-727115,756-1%-$31,356+3-5+2
D
2017-02-06
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale+OE$43.14-963117,666-1%-$41,544+3-5+2
D
2017-02-06
NBIXGano KyleChief Business Development OffS - Sale+OE$43.15-72761,311-1%-$31,370+3-5+2
DM
2017-02-06
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$43.35-8431,082-44%-$36,545+3-5+2
D
2017-02-06
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale+OE$43.17-1,20637,038-3%-$52,063+3-5+2
DM
2017-02-06
NBIXBenevich EricChief Commercial OfficerS - Sale+OE$43.32-9531,222-44%-$41,287+3-5+2
DM
2017-02-06
NBIXLippoldt DarinGCS - Sale+OE$43.34-9531,222-44%-$41,300+3-5+2
2017-02-06
NBIXCoughlin Timothy PCFOS - Sale$43.14-963137,961-1%-$41,544+3-5+2
D
2017-02-06
NBIXGorman Kevin CharlesCEOS - Sale+OE$43.18-3,010314,703-1%-$129,972+3-5+2
2017-02-03
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$42.57-1,375116,079-1%-$58,534+1+3+1
2017-02-03
NBIXCoughlin Timothy PCFOS - Sale$42.55-1,500136,324-1%-$63,825+1+3+1
2017-02-03
NBIXGano KyleChief Business Development OffS - Sale$42.57-1,37560,113-2%-$58,534+1+3+1
2017-02-03
NBIXGorman Kevin CharlesCEOS - Sale$42.55-3,125247,802-1%-$132,969+1+3+1
2017-02-03
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$42.56-1,375114,558-1%-$58,520+1+3+1
2017-02-03
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$42.50-1,50035,044-4%-$63,750+1+3+1
D
2017-02-01
NBIXRastetter William HDirS - Sale+OE$42.28-10,75014,250-43%-$454,510+3+4+4
2017-01-17
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$40.63-1,625114,704-1%-$66,024-1-5+1
2017-01-17
NBIXCoughlin Timothy PCFOS - Sale$40.65-1,750134,824-1%-$71,138-1-5+1
2017-01-17
NBIXGano KyleChief Business Development OffS - Sale$40.65-1,62558,738-3%-$66,056-1-5+1
2017-01-17
NBIXGorman Kevin CharlesCEOS - Sale$40.65-3,750244,677-2%-$152,438-1-5+1
2017-01-17
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$40.63-1,625113,183-1%-$66,024-1-5+1
2017-01-17
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$40.66-1,75033,544-5%-$71,155-1-5+1
2017-01-10
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$43.35-1,75031,794-5%-$75,863+3+1+8
2017-01-10
NBIXGrigoriadis Dimitri E.CHIEF RESEARCH OFFICERS - Sale$43.39-1,625111,558-1%-$70,509+3+1+8
2017-01-10
NBIXGorman Kevin CharlesCEOS - Sale$43.28-3,750240,927-2%-$162,300+3+1+8
2017-01-10
NBIXGano KyleChief Business Development OffS - Sale$43.37-1,25057,113-2%-$54,213+3+1+8
2017-01-10
NBIXCoughlin Timothy PCFOS - Sale$43.37-1,750133,124-1%-$75,898+3+1+8
2017-01-10
NBIXBozigian Haig P.CHIEF DEVELOPMENT OFFICERS - Sale$43.37-1,625113,079-1%-$70,476+3+1+8
2016-11-15
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$52.84-25,00030,044-45%-$1,321,000-3-7-17
D
2016-09-01
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$50.00-9,0000-100%-$450,000-1-20-13
2016-08-15
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$48.73-12,50055,044-19%-$609,125-1+7+7-14
2016-08-08
NBIXNevinny Corinne HDirS - Sale$48.54-5,00025,555-16%-$242,700-30+4-11
D
2016-05-31
NBIXLloyd-Smith MalcolmChief Regulatory OfficerS - Sale+OE$50.00-9,0000-100%-$450,000-2+2-11-5
2016-05-31
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$50.00-12,50067,544-16%-$625,000-2+2-11-5
2016-05-25
NBIXPops Richard FDirS - Sale$46.72-15,00015,464-49%-$700,800+1+11-5+7
2016-05-16
NBIXObrien Christopher FlintCHIEF MEDICAL OFFICERS - Sale$45.00-25,00080,044-24%-$1,125,000+3+7+1+21

Real-time CSV? Options? Alerts? Contact us!
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top